Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients-Reference-Cited by-同舟云学术

Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients

Published:2024-08-29 Issue: Volume: Page:
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Giunta Emilio Francesco^ORCID,Caroli Paola,Scarpi Emanuela,Altavilla Amelia,Rossetti Virginia,Marini Irene,Celli Monica,Casadei Chiara,Lolli Cristian,Schepisi Giuseppe,Bleve Sara,Brighi Nicole,Cursano Maria Concetta,Paganelli Giovanni,Matteucci Federica,De Giorgi Ugo

Funder

Ricerca Corrente by the Italian Ministry of Health.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06887-4.pdf

Reference41 articles.

1. Survival Rates for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html accessed on 1st June 2024.

2. Miyahira AK, Soule HR. The history of Prostate-Specific Membrane Antigen as a theranostic target in prostate Cancer: the cornerstone role of the prostate Cancer Foundation. J Nucl Med. 2022;63(3):331–8. https://doi.org/10.2967/jnumed.121.262997.

3. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807–11.

4. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.

5. Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, Castellucci P. Current and emerging clinical applications of PSMA PET Diagnostic imaging for prostate Cancer. J Nucl Med. 2021;62(5):596–604.